AMBER ANGELIDIS: Open Payments
NPI 1174003974 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$637 in 32 payments from 15 companies in 2025. Trend: 2023 $140 · 2024 $787 · 2025 $637
Food & beverage: $616Education: $20
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 9 | $156 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $79 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 2 | $58 |
| Ardelyx, Inc. | 3 | $56 |
| AKEBIA THERAPEUTICS INC | 1 | $28 |
| Vifor Pharma, Inc. | 1 | $24 |
| CorMedix Inc. | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
Products named: VELPHORO, JARDIANCE, Kerendia, IBSRELA, VOYXACT, JYNARQUE, Vafseo, Veltassa.
Industry payments across VA — which companies pay providers there.
